Equity Profile

KYMR

Kymera Therapeutics, Inc.

Health CareBiotechnology$6.4B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Kymera Therapeutics Beats on EPS, Stock Down 0.5%

Metric	Actual	Expected	Surprise
EPS	$-0.71	$-0.86	+20.40%
Revenue	N/A	$8M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Kymera Therapeutics Beats on EPS, Stock Down 0.5%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.71	$-0.86	+20.40%
Revenue	N/A	$8M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Kymera Therapeutics reported a narrower loss per share than expected, which is a positive sign for the company. However, the stock reacted negatively, declining by 0.5%. This could indicate investor concerns despite the EPS beat, possibly due to the lack of revenue information and guidance.

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat serious diseases by harnessing the body's own immune system....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

-0.86

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat serious diseases by harnessing the body's own immune system. Operating in the health care sector, its work is significant as it addresses unmet medical needs through targeted protein degradation, a cutting-edge approach in drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-4.04%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In the last quarter, Kymera reported an EPS of -0.97, which was worse than analysts' expectations, leading to a slight decline in stock price. The company has not provided specific revenue figures, making it challenging to assess overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Kymera to report a loss this quarter, with a consensus EPS of -0.86 and revenue of $8 million. The market is watching closely for any signs of improvement in earnings or revenue growth.

Bull Case

If Kymera can exceed revenue expectations and narrow its losses, it could signal a turnaround in its business strategy, potentially boosting investor confidence.

Bear Case

Conversely, if the company fails to meet these expectations, it may raise concerns about its financial stability and ability to execute its growth plans.

Key Metrics to Watch

EPS

-0.86

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Kymera's revenue reach or exceed the $8 million consensus estimate?

Achieving or surpassing this revenue target would indicate strong market demand for its therapies and could positively influence investor sentiment.

How does management plan to address the ongoing losses reflected in the EPS?

Investors will be keen to hear strategies for improving profitability, as continued losses could raise concerns about the company's long-term viability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Kymera to achieve a revenue turnaround, as recent developments in its pipeline could lead to unexpected demand.

Supporting Evidence

The options market is pricing a 6.39% move, indicating expectations of volatility that may not align with the company's actual performance.

Kymera's recent insider selling may suggest a lack of confidence in immediate recovery, which could be misinterpreted by the market.

Key Risk

If Kymera's revenue comes in significantly above $8 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the potential for recovery against the backdrop of recent disappointing earnings.

Bull Confirmed If

Exceeding the consensus EPS of -0.86 and achieving revenue above $8 million would confirm a positive outlook.

Bear Confirmed If

Reporting a wider loss than expected or revenue below $8 million would reinforce bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±6.39%

Historical Avg

±4.4%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, suggesting that investors are anticipating volatility.

Options are pricing ±6.4% while KYMR has averaged ±4.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

38.4%

Calls (3K)P/C Ratio: 0.36Puts (13K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$2.1M

23,692 sh

3 insiders

Net

$2.1M

Net selling

Most Active Insiders· 11 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kymera beats expectations, history suggests a potential average one-day move of +1.98%, confirming a positive shift in investor sentiment.

In-Line / Cautious

An in-line report could lead to a muted reaction, with management commentary driving the stock's movement as investors assess future guidance.

Miss

If the company misses expectations, history suggests an average one-day move of -4.14%, likely leading to increased skepticism about its growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results that could impact revenue forecasts.
2Details on cost management strategies to address ongoing losses.
3Insights into market demand for Kymera's therapies and any new partnerships.
4Management's outlook on future revenue growth and profitability timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

VZReported

Verizon Communications Inc.

Congress activity

RecapView

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat serious diseases by harnessing the body's own immune system....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

-0.86

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-4.04%

Avg Stock Reaction

-3.15%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Kymera can exceed revenue expectations and narrow its losses, it could signal a turnaround in its business strategy, potentially boosting investor confidence.

Bear Case

Conversely, if the company fails to meet these expectations, it may raise concerns about its financial stability and ability to execute its growth plans.

Key Metrics to Watch

EPS

-0.86

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Kymera's revenue reach or exceed the $8 million consensus estimate?

Achieving or surpassing this revenue target would indicate strong market demand for its therapies and could positively influence investor sentiment.

How does management plan to address the ongoing losses reflected in the EPS?

Investors will be keen to hear strategies for improving profitability, as continued losses could raise concerns about the company's long-term viability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Kymera to achieve a revenue turnaround, as recent developments in its pipeline could lead to unexpected demand.

Supporting Evidence

The options market is pricing a 6.39% move, indicating expectations of volatility that may not align with the company's actual performance.

Kymera's recent insider selling may suggest a lack of confidence in immediate recovery, which could be misinterpreted by the market.

Key Risk

If Kymera's revenue comes in significantly above $8 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the potential for recovery against the backdrop of recent disappointing earnings.

Bull Confirmed If

Exceeding the consensus EPS of -0.86 and achieving revenue above $8 million would confirm a positive outlook.

Bear Confirmed If

Reporting a wider loss than expected or revenue below $8 million would reinforce bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±6.39%

Historical Avg

±4.4%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, suggesting that investors are anticipating volatility.

Options are pricing ±6.4% while KYMR has averaged ±4.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

38.4%

Calls (3K)P/C Ratio: 0.36Puts (13K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$2.1M

23,692 sh

3 insiders

Net

$2.1M

Net selling

Most Active Insiders· 11 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kymera beats expectations, history suggests a potential average one-day move of +1.98%, confirming a positive shift in investor sentiment.

In-Line / Cautious

An in-line report could lead to a muted reaction, with management commentary driving the stock's movement as investors assess future guidance.

Miss

If the company misses expectations, history suggests an average one-day move of -4.14%, likely leading to increased skepticism about its growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results that could impact revenue forecasts.
2Details on cost management strategies to address ongoing losses.
3Insights into market demand for Kymera's therapies and any new partnerships.
4Management's outlook on future revenue growth and profitability timelines.